Search Result

Results for "

Small molecular inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (1) Cadherin (1) CDK (1) Deubiquitinase (1) DNA/RNA Synthesis (2) Ferroptosis (1) Glutathione Peroxidase (1) HOXA (1) MAP3K (1) NEKs (1) NTPDase (3) Orphan Receptor (1) PGE synthase (1) Poly(ADP-ribose) Glycohydrolase (PARG) (1) Ras (1) Reactive Oxygen Species (ROS) (1) SARS-CoV (1) TNF Receptor (2)
By Research Areas:	Cancer (13) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (4) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Targets Recommended: Molecular Glues Small Interfering RNA (siRNA)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153607

HDAC-IN-55	Cadherin	Cancer
HDAC-IN-55(8j) is a small molecular compound that can increase the expression of E-cadherin and inhibit the proliferation of cancer cells .

HY-147416

Vipoglanstat BI 1029539; GS-248; OX-MPI	PGE synthase	Infection Cancer
Vipoglanstat (BI 1029539), a carboxamide, is a potent and selective, non-peptide and orally active small molecular inhibitor of human prostaglandin E synthase 1 (mPGES-1). Vipoglanstat also has anti-inflammatory activity .

HY-137924

JA2131	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
JA2131 is a small molecular inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG) (IC₅₀=0.4 μM). JA2131 regulate DNA damage responses, causes replication fork stalling and cancer cell death .

HY-103265

ARL67156 trisodium 2 Publications Verification FPL 67156 trisodium	NTPDase	Cardiovascular Disease Inflammation/Immunology
ARL67156 (FPL 67156) trisodium is a selective small molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12?μM, respectively. ARL67156 trisodium can be used in the research of calcific aortic valve disease, asthma .

HY-103265B

ARL67156 trisodium hydrate 2 Publications Verification FPL 67156 trisodium hydrate	NTPDase	Cardiovascular Disease Inflammation/Immunology
ARL67156 (FPL 67156) trisodium hydrate is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium hydrate is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma .

HY-103265D

ARL67156 triethylamine 2 Publications Verification FPL 67156 triethylamine	NTPDase	Cardiovascular Disease Inflammation/Immunology
ARL67156 (FPL 67156) triethylamine is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 triethylamine is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12 μM, respectively. ARL67156 triethylamine can be used in the research of disease like calcific aortic valve disease, asthma .

HY-176557

NCI677397	Deubiquitinase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Autophagy	Cancer
NCI677397 is a USP24 inhibitor. NCI677397 increases lipid ROS, activates cholesterol and fatty acid biosynthesis, degrades ABC transporters, GPX4 and DHFR through the autophagy pathway, decreases the level of P-gp and ultimately leads to ferroptosis in drug-resistant cancer cells. NCI677397 can be used for the study of lung caner and brain cancer .

HY-151287

KRAS inhibitor-20	Ras	Cancer
KRAS inhibitor-20 is a small molecular inhibitor of KRas ^G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRas ^G12C with the IC50 value <10 nM .

HY-161463

CDK2-IN-28	CDK	Cancer
CDK2-IN-28 (compound 22) is a CDK2 inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 μM) .

HY-118054

LRH-1 Inhibitor-3	Orphan Receptor	Cancer
LRH-1 Inhibitor-3 is a small molecule that inhibits LRH-1 transcriptional activity, thereby decreasing the expression of target genes associated with cell growth and proliferation. LRH-1 Inhibitor-3 has shown potential in reducing cancer cell proliferation in human pancreatic, colon, and breast adenocarcinoma cell lines. LRH-1 Inhibitor-3 serves as a molecular probe for investigating the role of LRH-1 in various malignancies.

HY-138155

NSC15520	DNA/RNA Synthesis	Cancer
NSC15520 is a small molecular inhibitor of Replication Protein A (RPA). NSC15520 specifically recognizes the RPA N-terminal DNA binding domain (DBD), and blocks the interaction of RPA with p53 or RAD9. NSC15520 also inhibtis helix destabilization of a duplex DNA (dsDNA) oligonucleotide, involves in DNA replication, DNA repair, DNA recombination, and DNA damage response signaling .

HY-P2612A

WP9QY TFA	TNF Receptor	Others Cancer
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)

HY-P2612

WP9QY	TNF Receptor	Others
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)

HY-150625

SARS-CoV-2 nsp13-IN-4	SARS-CoV	Infection
SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC₅₀ value of 57 μM. SARS-CoV-2 nsp13-IN-4 is agentlike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect .

HY-152247

DDO3711	MAP3K	Cancer
DDO3711, a PP5-recruiting phosphatase recruitment chimeras (PHORCs), is formed by connecting a small molecular apoptosis signal-regulated kinase 1 (ASK1) inhibitor to a PP5 activator through a chemical linker. DDO3711 specifically inhibits ASK1 (IC₅₀ =164.1 nM) not ASK2 (IC₅₀>20 μM). DDO3711 significantly dephosphorylates p-ASK1 ^T838 by recruiting PP5 and shows the ASK1-dependent antiproliferative activity. DDO3711 has anti-cancer activity and has the potential for abnormally phosphorylated oncoproteins research .

HY-153916

TCRS-417 T417	HOXA DNA/RNA Synthesis NEKs	Neurological Disease Inflammation/Immunology Cancer
TCRS-417 (T417) is a small-molecular inhibitor for PBX1. TCRS-417 can directly block PBX1-binding to DNA (IC₅₀ = 6.58 μM), and affects PBX1 transcription. TCRS-417 is able to hammer out the stemness traits of Carboplatin (HY-17393)-resistant (CR) cells to revert to a differentiated status through tacking PBX1 signaling cascade. TCRS-417 significantly suppresses self-renewal and proliferation of cancer cells expressing high levels of PBX1. TCRS-417 can decrease the mRNA levels of FOXM1, NEK2, and E2F2 in cancer cell lines. TCRS-417 is selectively toxic against chr1q-amp myeloma and solid tumor cells .

Cat. No.	Product Name

HY-L184

Anti-Gastric Cancer Compound Library	891 compounds
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 891 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Anti-Gastric Cancer Compound Library

891 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 891 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

HY-L147

Protease Inhibitor Library	754 compounds
A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. Proteases play important roles in regulating multiple biological processes in all living organisms, such as regulating the fate, localization, and activity of many proteins, modulating protein-protein interactions, creating new bioactive molecules, contributing to the processing of cellular information, and generating, transducing, and amplifying molecular signals. Proteases are important targets in drug discovery. Some protease inhibitors are often used as anti-virus drugs and anti-cancer drugs. MCE offers a unique collection of 754 protease inhibitors. MCE Protease Inhibitor Library is critical for drug discovery and development.

Protease Inhibitor Library

754 compounds

A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. Proteases play important roles in regulating multiple biological processes in all living organisms, such as regulating the fate, localization, and activity of many proteins, modulating protein-protein interactions, creating new bioactive molecules, contributing to the processing of cellular information, and generating, transducing, and amplifying molecular signals.

Proteases are important targets in drug discovery. Some protease inhibitors are often used as anti-virus drugs and anti-cancer drugs. MCE offers a unique collection of 754 protease inhibitors. MCE Protease Inhibitor Library is critical for drug discovery and development.

Cat. No.	Product Name	Target	Research Area

HY-P2612A

WP9QY TFA	TNF Receptor	Others Cancer
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)

HY-P2612

WP9QY	TNF Receptor	Others
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)

HY-106263A

Tyroserleutide TFA	Peptides	Cancer
Tyroserleutide TFA, isolated from the degradation products of porcine spleen , is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo .

HY-106263

Tyroserleutide	Peptides	Cancer
Tyroserleutide (YSL), isolated from the degradation products of porcine spleen , is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.